Global In Vitro Diagnostics (IVD) Quality Control Market to Reach $1.8 Billion by 2030
The global market for In Vitro Diagnostics (IVD) Quality Control estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at a CAGR of 2% over the analysis period 2022-2030. Clinical Chemistry, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$607.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunochemistry segment is readjusted to a revised 1.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $430.8 Million, While China is Forecast to Grow at 6.4% CAGR
The In Vitro Diagnostics (IVD) Quality Control market in the U.S. is estimated at US$430.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$437.6 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -1.2% and 0.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately -0.2% CAGR.Select Competitors (Total 32 Featured) -
- Abbott Laboratories
- Becton, Dickinson And Company (BD)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Eurotrol B.V.
- F. Hoffmann -La Roche Ltd.
- Fortress Diagnostics Limited
- Helena Biosciences Europe
- Maine Molecular Quality Controls, Inc.
- Merck KGaA
- Omega Diagnostics Group Plc
- Ortho Clinical Diagnostics
- Randox Laboratories Ltd.
- Seracare Life Sciences Inc.
- Sero As
- Siemens Ag
- Sun Diagnostics, LLC.
- Technopath Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- Zeptometrix Corporation
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Becton, Dickinson And Company (BD)
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Eurotrol B.V.
- F. Hoffmann -La Roche Ltd.
- Fortress Diagnostics Limited
- Helena Biosciences Europe
- Maine Molecular Quality Controls, Inc.
- Merck KGaA
- Omega Diagnostics Group Plc
- Ortho Clinical Diagnostics
- Randox Laboratories Ltd.
- Seracare Life Sciences Inc.
- Sero As
- Siemens Ag
- Sun Diagnostics, LLC.
- Technopath Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- Zeptometrix Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 88 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.6 Billion |
Forecasted Market Value ( USD | $ 1.8 Billion |
Compound Annual Growth Rate | 1.5% |
Regions Covered | Global |